AZ reports data from immunotherapy trial

September 10, 2019 Latest News

This is a preview of subscriber content

Subscribe now to continue reading.

As companies with lung cancer immunotherapies process the small level detail they received on the outcome of August's PBAC meeting at which the committee considered simplifying their reimbursement, AstraZeneca has announced new and positive results from its yet-to-be-listed IMFINZI (durvalumab). …

Subscribe now to continue reading.

Latest Video

The HTA Review and the 'Abilene paradox' - when everyone argues for reforms that nobody wants
August 3, 2026 - Latest News
Potential merger could create a new global oncology powerhouse
August 3, 2026 - Latest News
The risk to patients is that new pricing policies could swamp any benefit from the HTA Review
August 4, 2026 - Latest News
Arrotex Pharmaceuticals appoints experienced industry executive as CMO
August 4, 2026 - Latest News
First new brain cancer treatment listed on PBS after more than 20 years
August 3, 2026 - Latest News

AZ reports data from immunotherapy trial

This is a preview of subscriber content

Latest Video

Most Read

The HTA Review and the 'Abilene paradox' - when everyone argues for reforms that nobody wants

Potential merger could create a new global oncology powerhouse

The risk to patients is that new pricing policies could swamp any benefit from the HTA Review

Arrotex Pharmaceuticals appoints experienced industry executive as CMO

First new brain cancer treatment listed on PBS after more than 20 years

New Stories

Injunction blocks generic launch of key HIV combination medicine

Moderna begins Phase 1 trial of vaccine candidate against Bundibugyo Ebola Virus

Neuren reports record DAYBUE sales as royalties rise and global expansion nears

NSW urged to think pharmacy first as 250 pharmacists near completion of advanced training

If Australian companies shun their domestic market, who can blame multinationals?

The complete absence of patient power and agency makes this a health system outlier

Pharmac announces plan to revise its recently expanded patient advisory function

Sign In

AZ reports data from immunotherapy trial

This is a preview of subscriber content

Latest Video

Most Read

The HTA Review and the 'Abilene paradox' - when everyone argues for reforms that nobody wants

Potential merger could create a new global oncology powerhouse

The risk to patients is that new pricing policies could swamp any benefit from the HTA Review

Arrotex Pharmaceuticals appoints experienced industry executive as CMO

First new brain cancer treatment listed on PBS after more than 20 years

Follow Us

New Stories

Injunction blocks generic launch of key HIV combination medicine

Moderna begins Phase 1 trial of vaccine candidate against Bundibugyo Ebola Virus

Neuren reports record DAYBUE sales as royalties rise and global expansion nears

NSW urged to think pharmacy first as 250 pharmacists near completion of advanced training

If Australian companies shun their domestic market, who can blame multinationals?

The complete absence of patient power and agency makes this a health system outlier

Pharmac announces plan to revise its recently expanded patient advisory function